日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas

抗CD47抗体magrolimab联合obinutuzumab和venetoclax治疗复发或难治性惰性B细胞淋巴瘤

Lakhotia, Rahul; Melani, Christopher; Pittaluga, Stefania; Gordon, Max J; Phelan, James D; Muppidi, Jagan R; Tadese, Atekelt; Evans, Sarah; Jaffe, Elaine S; Staudt, Louis M; Wilson, Wyndham H; Roschewski, Mark

Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma

复发性弥漫性大B细胞淋巴瘤的联合靶向治疗

Melani, Christopher; Lakhotia, Rahul; Pittaluga, Stefania; Phelan, James D; Huang, Da Wei; Wright, George; Simard, Jillian; Muppidi, Jagan; Thomas, Craig J; Ceribelli, Michele; Tosto, Frances A; Yang, Yandan; Xu, Weihong; Davies-Hill, Theresa; Pack, Svetlana D; Peer, Cody J; Arisa, Oluwatobi; Mena, Esther; Lindenberg, Liza; Bergvall, Ethan; Portell, Craig A; Farah, Rafic J; Lee, Seung Tae; Pradhan, Amynah; Morrison, Candis; Tadese, Atekelt; Juanitez, Anna Marie; Lu, Crystal; Jacob, Allison; Simmons, Heidi; Figg, William D; Steinberg, Seth M; Jaffe, Elaine S; Roschewski, Mark; Staudt, Louis M; Wilson, Wyndham H